Experts discussed the achievement of Russia's drug sovereignty

Experts discussed the achievement of Russia's drug sovereignty

The participants of the Healthy Society forum discussed the contribution of all levels of the pharmaceutical industry to ensuring the country's drug safety. During the session "Components of safety: the contribution of each link in the pharmaceutical industry", representatives of government, science and business assessed the interim results of import substitution and the prospects for the transition to innovative pharmaceuticals.

The session was opened by Deputy, member of the State Duma Committee on Health Alexander Petrov. He noted the work of the relevant institutes and emphasized the significant role of interdisciplinary cooperation between all industry participants. According to him, this is especially true during periods of great challenges, such as the COVID-19 pandemic and its

Among the support measures provided to Russian drug manufacturers, Ekaterina Priezdeva, Deputy Minister of Industry and Trade of the Russian Federation, recalled compensation for the costs of the final phase of clinical trials of best-in-class and first-in-class drugs. Thus, in 2025, for 88 of the 186 international nonproprietary names that had not previously been produced in the country, domestic companies received 294 registration certificates, she noted.

Speaking about the goals of drug sovereignty, Dmitry Kudlay, Vice President of Generium JSC, Corresponding Member of the Russian Academy of Sciences, noted that the development of new technologies can and should take place taking into account the best international practices. He drew attention to the speech of Russian President Vladimir Putin at the Forum of Future Technologies in 2024, in which he noted that cooperation with Western specialists was envisaged. As an example, Kudlay cited the Allergarda birch pollen allergy vaccine project, which was the result of long-term and well-coordinated work by an international team with the participation of a foreign academician of the Russian Academy of Sciences, Professor Rudolf Valenta.

The expert stressed that the core competencies and technological capabilities should be concentrated in Russia. "If there is a question about technologies that are called vital and strategic, we must define the level of "our own" and "others" very clearly," Kudlay said. He added that the entire link of technological solutions in this area should lie within the country, even if the development is carried out jointly with foreign partners.

The speaker also called on all participants in the process to take into account the guidelines set by the state — the goals of national development outlined in the presidential decree "On the National Development Goals of the Russian Federation for the period up to 2030 and for the future up to 2036." In addition, Kudlay recalled the tasks of achieving independence and technological leadership outlined in the resolution "On Approval of the Regulations on the Scientific and Technical Council of the Commission for Scientific and Technological Development of the Russian Federation."

The session was attended by representatives of regulators and science, including Alla Samoilova, Head of Roszdravnadzor, Sergey Glagolev, Deputy Minister of Health of the Russian Federation, and Vadim Tarasov, Vice-rector of Sechenov University. Representatives of pharmaceutical manufacturers also participated in the discussion — Irina Panarina, General Director of AstraZeneca Russia and Eurasia, Kirill Danishevsky, Vice President for Corporate Communications at NPO Petrovax Pharm, and Alice Dzhangiryants, Deputy General Director for Access to the Market and Oncology at Svix Healthcare LLC.

In particular, the participants discussed the effectiveness of the drug labeling system, the role of the Ministry of Health as a qualified customer of medicines, and the prospects for the industry's transition from a generic model to an innovative one. Speaking about the latter, Tarasov stressed that the demand for science appears only when the industry reaches the innovative stage. "If the industry is generic, it doesn't need science, if the industry is moving to the innovation stage, there is a demand for original products," he noted.

According to the expert, the transition from "repair medicine" to health management is already underway. Drugs based on DC technology, T-cell therapy, oncolytic viruses, and microbiome therapy will completely change the market in the next five years. At the same time, new products are highly likely to be built on those technological platforms that currently produce the leading classical medicines. Therefore, it is very important for Russian scientists and manufacturers to master the basic technology in order to make new things in the future.

Alla Samoilova, Head of the Federal Service for Healthcare Supervision, in turn, spoke about the effectiveness of the drug labeling system introduced in Russia since 2020. "It is a tool for monitoring, monitoring, forecasting, and real work with patients, suppliers, and manufacturers. We see which medicines are in circulation, what is in stock, what is lying motionless," she recalled.

All important news is on the Izvestia channel in the MAX messenger.